A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Cetuximab (Primary) ; Glecirasib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Allist Pharmaceuticals; Jacobio Pharmaceuticals
Most Recent Events
- 13 Mar 2025 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 20 Aug 2024 Planned End Date changed from 1 Jan 2026 to 1 Dec 2024.
- 20 Aug 2024 Status changed from recruiting to active, no longer recruiting.